New Haven
-
FDA Refuses to Review Biohaven Drug for Rare Neuromuscular Disease With No Treatments
Biohaven’s bid to bring to market the first drug for rare neuromuscular disorder spinocerebellar ataxia has hit a setback. The FDA is refusing to review the drug’s application, a decision that could indicate the agency wants another clinical trial.
-
Biohaven drug fails another clinical test, this time in rare neuromuscular disorder
Biohaven’s migraine drug research led to an FDA-approved product with strong commercial uptake, but its other neuroscience efforts have yet to achieve the same outcomes. Drug candidate troriluzole has failed a Phase 3 test in neuromuscular disorder spinocerebellar ataxia, the molecule’s third failure in a pivotal study in the past two years.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Pfizer buys its way into migraine with $11.6B Biohaven Pharma acquisition
Pfizer is turning to M&A to get its next blockbuster, buying Biohaven six months after the two companies began a commercialization pact centered on the oral migraine drug Nurtec. The acquisition will lead to the spinout of Biohaven’s other assets into a new, publicly traded company capitalized with $275 million.
-
Biohaven migraine drug partnered with Pfizer lands twin European approvals
The European Commission approved Biohaven Pharmaceuticals migraine drug rimegepant. While the regulatory decision marks another milestone for Biohaven, it’s also a win for Pfizer, which holds rights to commercialize the drug outside of the U.S.
-
Biohaven pays $100M for epilepsy drug prospect; strikes deal for BMS muscle med
Neuroscience drug developer Biohaven Pharmaceuticals is expanding its pipeline to include epilepsy and spinal muscular atrophy. The drug developer is acquiring Channel Bioscience and licensing global rights to a Phase 3-ready drug from Bristol Myers Squibb.
-
Biohaven’s migraine progress pays off with a Pfizer marketing pact for two drugs
Biohaven Pharmaceuticals has seen strong U.S. market uptake for its oral migraine drug, Nurtec. With regulatory decisions looming around the world, the company has landed the marketing muscle of Pfizer, which is paying $500 million up front for the right to market that drug and another clinical-stage compound outside of the U.S.
-
Biohaven drug licensed from AstraZeneca fails Phase 3 test in rare neuro disorder
Biohaven’s bet on an AstraZeneca drug for multiple system atrophy does not pan out, failing a pivotal study in the rare, neurodegenerative disorder. But a separate Phase 3 study evaluating verdiperstat in amyotrophic lateral sclerosis is still moving forward.
-
Pfizer commits $1B to Arvinas for share of protein degrading breast cancer drug
Arvinas’ early clinical data for its targeted protein degradation drug for breast cancer drew partnering interest from several companies. Pfizer beat them all with a deal that pays the biotech $1 billion to share in the development and commercialization of this therapy.
-
Melinta antibiotic for MRSA & other serious skin infections wins FDA approval
Melinta Therapeutics already sells an antibiotic for serious skin infections. But FDA approval of Kimyrsa gives clinicians another option to offer patients, one with more convenient dosing.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
AARP Foundation files class action suit against Yale University over employee wellness program
The complaint alleges that the program, which involves workers undergoing certain medical examinations and divulging health info in lieu of a weekly fine is a violation of the American with Disabilities Act and the Genetic Nondiscrimination Act.
-
PatientWisdom pulls in $1M to improve digital engagement platforms
OCA Ventures is the newest investor in the New Haven, Connecticut-based startup, which has raised another $1 million in its Series A round of funding.
-
Pfizer and Arvinas sign $830M drug development deal that target proteins causing disease
Pfizer is paying big bucks for yet-to-be-discovered small molecule drugs that can break down harmful proteins in diseases such as cancer and Alzheimer’s.
-
OSF Ventures invests in PatientWisdom
The corporate investment arm of Peoria, Illinois-based OSF HealthCare is investing in the New Haven, Connecticut-based company’s technology, which seeks to improve the patient experience.
-
Yale, Appriss Health and Connecticut partner to combat opioid abuse
As the opioid crisis continues to be top of mind in America, Yale New Haven Health, Yale School of Medicine, Appriss Health and the State of Connecticut have teamed up to better tackle abuse.
-
Inbox Health raises more capital in quest to empower physician’s practices
Inbox Health is investing in neural networks that examine insurance claim data and blockchain technology to remove the guesswork out of what patient’s owe when they visit the doctor’s office.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
